The Experts below are selected from a list of 2079 Experts worldwide ranked by ideXlab platform
Michel Leclerc - One of the best experts on this subject based on the ideXlab platform.
-
ANOTHER CANDIDATE IG KAPPA-LIKE GENE IN
2016Co-Authors: The Sea, Star A. Rubens, Michel LeclercAbstract:In a recent paper we have shown that Ig Kappa genes (region MOPC 63, region K2), of 250 nucleotides each, were present in the sea star Asterias rubens. Two years later, a 697 nucleotide Ig Kappa chain V-V region K2 gene was accentuated
-
HUMORAL IMMUNE RESPONSES TO VARIOUS ANTIGENS IN THE ASTERIDS: A.GIBBOSA AND A.RUBENS
2016Co-Authors: Michel LeclercAbstract:Immunizations with various antigens of the sea stars Asterina gibbosa and Asterias rubens produce specific humoral immune reactions which initiate the antibody factor. This antibody factor is correlated with kappa genes and could be composed of 4 kappa chains. It is the first time that such phenomenom was described in an invertebrate
-
a true 34candidate ig kappa gene 34 in the sea star Asterias rubens echinoderma
American Journal of Immunology, 2013Co-Authors: Michel Leclerc, Patricia Otten, Magne OsterasAbstract:The axial organ of the sea-star Asterias rubens is a primitive immune organ. The B-like cells, when stimulated by various antigens, produce antibody substances correlated with Ig Kappa gene. A candidate Ig kappa gene (IgK chain V-IV region S107B precursor) more convincing in term of genome was shown.
-
Evidence of Interleukin Genes in the Sea-Star: Asterias rubens (Echinoderma)
American Journal of Immunology, 2013Co-Authors: Michel Leclerc, Patricia OttenAbstract:The axial organ of the sea star Asterias rubens is a primitive immune organ the sea star T lymphocytes, when stimulated by various lectins, produce lymphokin-like substances with mitogenic properties as shown in earlier studies; they are correlated with Interleukin genes.
-
Innate and Adaptative Immunity in the Sea-Star Asterias Rubens
American Journal of Immunology, 2012Co-Authors: Michel LeclercAbstract:The axial organ of the sea star Asterias rubens is a primitive immune organ. The B-like cells, when stimulated by various antigens, produce antibody substances correlating with Mouse Ig Kappa genes. On the other hand elements of the innate immunity are present in Asterias rubens such as Toll-like receptors, interleukin receptors, complement components which contribute to initiate the «antibody factor».
James L. Zazzali - One of the best experts on this subject based on the ideXlab platform.
-
angioedema in the omalizumab chronic idiopathic spontaneous urticaria pivotal studies
Annals of Allergy Asthma & Immunology, 2016Co-Authors: James L. Zazzali, Evgeniya Antonova, Benjamin Trzaskoma, Karina Raimundo, Allen Kaplan, Marcus Maurer, Paul G Solari, Meryl Mendelson, Karin RosénAbstract:Abstract Background Angioedema, present in some patients with chronic idiopathic/spontaneous urticaria (CIU/CSU), may have a negative effect on patient quality of life. Objective To describe patient-reported angioedema and its management in the pivotal omalizumab studies (ASTERIA I, ASTERIA II, GLACIAL). Methods Enrolled patients with CIU/CSU remained symptomatic despite treatment with histamine 1 (H 1 )-antihistamines at licensed doses (ASTERIA I, ASTERIA II) or H 1 -antihistamines at up to 4 times the approved dose plus H 2 -antihistamines and/or a leukotriene receptor antagonist (GLACIAL). All studies administered omalizumab (75, 150, or 300 mg in ASTERIA I and ASTERIA II; 300 mg in GLACIAL) or placebo subcutaneously every 4 weeks for at least 12 weeks. Urticaria Patient Daily Diary entries were completed by patients and summarized. Results At baseline, angioedema prevalence was higher in GLACIAL (53.1%) than in ASTERIA I (47.5%) or ASTERIA II (40.7%). The mean proportion of angioedema-free days during weeks 4 to 12 was greater for patients treated with 300 mg of omalizumab than placebo in ASTERIA I (96.1% vs 88.2%, P P P = .006). Most patient-reported angioedema was managed by low-intensity interventions (doing nothing or taking medication). Conclusion Treatment with 300 mg of omalizumab was efficacious in reducing patient-reported angioedema. Low-intensity interventions were generally used to manage angioedema episodes. Trial Registration clinicaltrials.gov Identifiers: NCT01287117 (ASTERIA I), NCT01292473 (ASTERIA II), and NCT01264939 (GLACIAL).
-
timing and duration of omalizumab response in patients with chronic idiopathic spontaneous urticaria
The Journal of Allergy and Clinical Immunology, 2016Co-Authors: Allen P. Kaplan, Marta Ferrer, Jonathan A. Bernstein, Evgeniya Antonova, Benjamin Trzaskoma, Karina Raimundo, Karin Rosén, Theodore A. Omachi, Sam Khalil, James L. ZazzaliAbstract:Background Few data are available that describe response patterns in patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) treated with omalizumab. Objective We sought to describe response patterns by using data from the 3 pivotal omalizumab CIU/CSU trials. Methods Every 4 weeks, randomized patients received dosing with placebo or 75, 150, or 300 mg of omalizumab (ASTERIA I: n = 318, 24 weeks; ASTERIA II: n = 322, 12 weeks) or placebo or 300 mg of omalizumab (GLACIAL: n = 335, 24 weeks). Response was defined as well-controlled urticaria (weekly Urticaria Activity Score [UAS7] ≤ 6) or complete response (UAS7 = 0). Results Response rates were dose dependent and highest with 300 mg of omalizumab. Some patients responded early (before week 4). At week 12, a higher proportion of patients treated with 300 mg of omalizumab reported a UAS7 ≤ 6 (26.0% [75 mg of omalizumab], 40.0% [150 mg of omalizumab], 51.9% [300 mg of omalizumab], and 11.3% [placebo] for ASTERIA I; 26.8% [75 mg of omalizumab], 42.7% [150 mg of omalizumab], 65.8% [300 mg of omalizumab], and 19.0% [placebo] for ASTERIA II; and 52.4% [300 mg of omalizumab] and 12.0% [placebo] for GLACIAL) or a UAS7=0 (11.7% [75 mg of omalizumab], 15.0% [150 mg of omalizumab], 35.8% [300 mg of omalizumab], and 8.8% [placebo] for ASTERIA I; 15.9% [75 mg of omalizumab], 22.0% [150 mg of omalizumab], 44.3% [300 mg of omalizumab], and 5.1% [placebo] for ASTERIA II; and 33.7% [300 mg of omalizumab] and 4.8% [placebo] for GLACIAL). In patients receiving 300 mg of omalizumab with 24 weeks of treatment, median time to achieve a UAS7 ≤ 6 was 6 weeks (ASTERIA I and GLACIAL) and median time to achieve a UAS7=0 was 12 or 13 weeks (ASTERIA I and GLACIAL, respectively). Some patients who achieved well-controlled urticaria or complete response sustained response throughout the treatment period. Conclusion Benefits of omalizumab treatment were evident early (before week 4) in some patients and persisted to week 24. Use of 300 mg of omalizumab demonstrated best results in controlling CIU/CSU symptoms.
Karin Rosén - One of the best experts on this subject based on the ideXlab platform.
-
angioedema in the omalizumab chronic idiopathic spontaneous urticaria pivotal studies
Annals of Allergy Asthma & Immunology, 2016Co-Authors: James L. Zazzali, Evgeniya Antonova, Benjamin Trzaskoma, Karina Raimundo, Allen Kaplan, Marcus Maurer, Paul G Solari, Meryl Mendelson, Karin RosénAbstract:Abstract Background Angioedema, present in some patients with chronic idiopathic/spontaneous urticaria (CIU/CSU), may have a negative effect on patient quality of life. Objective To describe patient-reported angioedema and its management in the pivotal omalizumab studies (ASTERIA I, ASTERIA II, GLACIAL). Methods Enrolled patients with CIU/CSU remained symptomatic despite treatment with histamine 1 (H 1 )-antihistamines at licensed doses (ASTERIA I, ASTERIA II) or H 1 -antihistamines at up to 4 times the approved dose plus H 2 -antihistamines and/or a leukotriene receptor antagonist (GLACIAL). All studies administered omalizumab (75, 150, or 300 mg in ASTERIA I and ASTERIA II; 300 mg in GLACIAL) or placebo subcutaneously every 4 weeks for at least 12 weeks. Urticaria Patient Daily Diary entries were completed by patients and summarized. Results At baseline, angioedema prevalence was higher in GLACIAL (53.1%) than in ASTERIA I (47.5%) or ASTERIA II (40.7%). The mean proportion of angioedema-free days during weeks 4 to 12 was greater for patients treated with 300 mg of omalizumab than placebo in ASTERIA I (96.1% vs 88.2%, P P P = .006). Most patient-reported angioedema was managed by low-intensity interventions (doing nothing or taking medication). Conclusion Treatment with 300 mg of omalizumab was efficacious in reducing patient-reported angioedema. Low-intensity interventions were generally used to manage angioedema episodes. Trial Registration clinicaltrials.gov Identifiers: NCT01287117 (ASTERIA I), NCT01292473 (ASTERIA II), and NCT01264939 (GLACIAL).
-
timing and duration of omalizumab response in patients with chronic idiopathic spontaneous urticaria
The Journal of Allergy and Clinical Immunology, 2016Co-Authors: Allen P. Kaplan, Marta Ferrer, Jonathan A. Bernstein, Evgeniya Antonova, Benjamin Trzaskoma, Karina Raimundo, Karin Rosén, Theodore A. Omachi, Sam Khalil, James L. ZazzaliAbstract:Background Few data are available that describe response patterns in patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) treated with omalizumab. Objective We sought to describe response patterns by using data from the 3 pivotal omalizumab CIU/CSU trials. Methods Every 4 weeks, randomized patients received dosing with placebo or 75, 150, or 300 mg of omalizumab (ASTERIA I: n = 318, 24 weeks; ASTERIA II: n = 322, 12 weeks) or placebo or 300 mg of omalizumab (GLACIAL: n = 335, 24 weeks). Response was defined as well-controlled urticaria (weekly Urticaria Activity Score [UAS7] ≤ 6) or complete response (UAS7 = 0). Results Response rates were dose dependent and highest with 300 mg of omalizumab. Some patients responded early (before week 4). At week 12, a higher proportion of patients treated with 300 mg of omalizumab reported a UAS7 ≤ 6 (26.0% [75 mg of omalizumab], 40.0% [150 mg of omalizumab], 51.9% [300 mg of omalizumab], and 11.3% [placebo] for ASTERIA I; 26.8% [75 mg of omalizumab], 42.7% [150 mg of omalizumab], 65.8% [300 mg of omalizumab], and 19.0% [placebo] for ASTERIA II; and 52.4% [300 mg of omalizumab] and 12.0% [placebo] for GLACIAL) or a UAS7=0 (11.7% [75 mg of omalizumab], 15.0% [150 mg of omalizumab], 35.8% [300 mg of omalizumab], and 8.8% [placebo] for ASTERIA I; 15.9% [75 mg of omalizumab], 22.0% [150 mg of omalizumab], 44.3% [300 mg of omalizumab], and 5.1% [placebo] for ASTERIA II; and 33.7% [300 mg of omalizumab] and 4.8% [placebo] for GLACIAL). In patients receiving 300 mg of omalizumab with 24 weeks of treatment, median time to achieve a UAS7 ≤ 6 was 6 weeks (ASTERIA I and GLACIAL) and median time to achieve a UAS7=0 was 12 or 13 weeks (ASTERIA I and GLACIAL, respectively). Some patients who achieved well-controlled urticaria or complete response sustained response throughout the treatment period. Conclusion Benefits of omalizumab treatment were evident early (before week 4) in some patients and persisted to week 24. Use of 300 mg of omalizumab demonstrated best results in controlling CIU/CSU symptoms.
Jens K. Petersen - One of the best experts on this subject based on the ideXlab platform.
-
Bioenergetics of the common seastar Asterias rubens: a keystone predator and pest for European bivalve culture
Marine Biology, 2021Co-Authors: Antonio Agüera, Camille Saurel, Lene F. Møller, Isla Fitridge, Jens K. PetersenAbstract:Losses due to predation are recognized as an important factor affecting shellfish stocks, restoration efforts and aquaculture production. Managing and mitigating the impact of predators require information on the population dynamics and functional responses to prey availability under varying environmental conditions. Asterias spp. are well-known keystone predators with the capacity to exert a top down control on shellfish populations. Asterias spp . populations are extremely plastic, booming fast when prey is abundant and exhibiting a remarkable individual resilience to starvation and adverse environmental conditions. These aspects have led Asterias spp . to be considered pests by shellfish producers and fishers and to be catalogued among the most devastating invasive species. Assessment and mitigation of the impact of Asterias rubens in northern Europe have been the objective of several projects. However, there is still a limited understanding of the processes behind A. rubens population plasticity and how environmental conditions affect individual growth and predation. Under these circumstances a comprehensive eco-physiological model becomes necessary. These models can integrate available information on biology and eco-physiology to gain understanding of the effect of the environmental conditions on the impact of A. rubens . In this work, we performed a number of eco-physiological experiments and combined them with field data from a Danish estuary to estimate and validate the parameters of a dynamic energy budget (DEB) model for the whole life cycle of A. rubens . DEB models can be used to assess the effects of environmental variability on the life cycle and key population traits allowing the prediction of the performance, abundance, resource requirements and potential distribution of individuals and populations under dynamic environments. As such the DEB model presented in this study aims to become a tool to be used to assess and manage the impact of A. rubens in cultured and natural shellfish populations. The successfully parameterised DEB model describes A. rubens as a plastic species, an efficient predator with low maintenance costs and, at least while feeding on mussels, a high energy yield from its prey. The model validation against independent data resulted in the model being capable to assess growth, food demand, reproductive output and reserves dynamics of A. rubens under experimental and natural conditions. Moreover, application of the model to the Limfjorden seastar fishery is used to further discuss the use of the model to understand biology and ecology of this pest species in the context with the management of shellfish stocks and impact mitigation.
Stefano Mariani - One of the best experts on this subject based on the ideXlab platform.
-
multiple paternity in the starry smooth hound shark mustelus Asterias carcharhiniformes triakidae
Biological Journal of The Linnean Society, 2014Co-Authors: Edward D Farrell, Niall Osullivan, Carlotta Sacchi, Stefano MarianiAbstract:Multiple paternity was investigated in the starry smooth-hound shark, Mustelus Asterias Cloquet, 1821. Analysis of 12 pregnant females and their embryos, at four microsatellite loci, showed that at least 58% carried multiply-sired litters. Paternal skew was observed, with one male siring most of the embryos within a litter, although no patterns of association were detected between the identity of the father and the size or the uterine position of the embryos. Sperm storage was observed in the oviducal glands of all twelve females. Results shed light on the complexity of reproductive strategies and selective processes in M. Asterias. © 2013 The Linnean Society of London, Biological Journal of the Linnean Society, 2014, 111, 119–125.
